These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 10925331)

  • 61. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
    Tcheng JE
    Am Heart J; 2000 Feb; 139(2 Pt 2):S38-45. PubMed ID: 10650315
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Percutaneous coronary interventions in octogenarians. glycoprotein IIb/IIIa receptor inhibitors' safety profile.
    Sadeghi HM; Grines CL; Chandra HR; Dixon SR; Boura JA; Dukkipati S; Harjai KJ; O'Neill WW
    J Am Coll Cardiol; 2003 Aug; 42(3):428-32. PubMed ID: 12906967
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
    Vorchheimer DA; Badimon JJ; Fuster V
    JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Pinto DS; Sperling RT; Tu TM; Cohen DJ; Carrozza JP
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):65-8. PubMed ID: 12508198
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes.
    Mak KH; Moliterno DJ
    Curr Cardiol Rep; 1999 Sep; 1(3):199-205. PubMed ID: 10980842
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era.
    Konstance R; Tcheng JE; Wightman MB; Kelly LP; Moore A; Harrison JK; Sketch MH
    J Interv Cardiol; 2004 Apr; 17(2):65-70. PubMed ID: 15104767
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.
    Wholey MH; Wholey MH; Eles G; Toursakissian B; Bailey S; Jarmolowski C; Tan WA
    J Endovasc Ther; 2003 Feb; 10(1):33-41. PubMed ID: 12751927
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
    King S; Short M; Harmon C
    Vascul Pharmacol; 2016 Mar; 78():10-6. PubMed ID: 26187354
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis.
    Brinjikji W; Morales-Valero SF; Murad MH; Cloft HJ; Kallmes DF
    AJNR Am J Neuroradiol; 2015 Jan; 36(1):121-5. PubMed ID: 25082819
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [New thrombocyte aggregation inhibitor in therapy of unstable angina].
    Hamm C
    Z Kardiol; 2000 Nov; 89(11):1053-6. PubMed ID: 11149273
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 72. Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors.
    Aster RH; Curtis BR; Bougie DW
    Semin Thromb Hemost; 2004 Oct; 30(5):569-77. PubMed ID: 15497099
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
    Kini AS; Reich D; Mitre CA; Sharma SK
    Am J Cardiol; 2001 Dec; 88(11):1287-90. PubMed ID: 11728356
    [No Abstract]   [Full Text] [Related]  

  • 74. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Gibson CM; Moynihan JL; Al-Mousa EN; Campsey M; Gandhi R; Murphy S; Mattson S; Ryan KA; Mesley R; Swanson J; Arshad MN; Marble SJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):287-302. PubMed ID: 10375390
    [No Abstract]   [Full Text] [Related]  

  • 75. Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions.
    Mandava P; Thiagarajan P; Kent TA
    Drugs; 2008; 68(8):1019-28. PubMed ID: 18484795
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.
    Kondo K; Umemura K
    Clin Pharmacokinet; 2002; 41(3):187-95. PubMed ID: 11929319
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 78. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists.
    Huxtable LM; Tafreshi MJ; Rakkar AN
    Am J Cardiol; 2006 Feb; 97(3):426-9. PubMed ID: 16442410
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Glycoprotein IIb/IIIa inhibitors.
    Stevens M
    Intensive Crit Care Nurs; 2002 Feb; 18(1):64-6. PubMed ID: 12008879
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
    Kereiakes DJ; McDonald M; Broderick T; Roth EM; Whang DD; Martin LH; Howard WL; Schneider J; Shimshak T; Abbottsmith CW
    Am Heart J; 2000 Feb; 139(2 Pt 2):S53-60. PubMed ID: 10650317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.